Literature DB >> 35903003

Microbiota-derived metabolites as drivers of gut-brain communication.

Hany Ahmed1, Quentin Leyrolle2, Ville Koistinen1,3, Olli Kärkkäinen4, Sophie Layé5, Nathalie Delzenne2, Kati Hanhineva1,3,6.   

Abstract

Alterations in the gut microbiota composition have been associated with a range of neurodevelopmental, neurodegenerative, and neuropsychiatric disorders. The gut microbes transform and metabolize dietary- and host-derived molecules generating a diverse group of metabolites with local and systemic effects. The bi-directional communication between brain and the microbes residing in the gut, the so-called gut-brain axis, consists of a network of immunological, neuronal, and endocrine signaling pathways. Although the full variety of mechanisms of the gut-brain crosstalk is yet to be established, the existing data demonstrates that a single metabolite or its derivatives are likely among the key inductors within the gut-brain axis communication. However, more research is needed to understand the molecular mechanisms underlying how gut microbiota associated metabolites alter brain functions, and to examine if different interventional approaches targeting the gut microbiota could be used in prevention and treatment of neurological disorders, as reviewed herein.Abbreviations:4-EPS 4-ethylphenylsulfate; 5-AVA(B) 5-aminovaleric acid (betaine); Aβ Amyloid beta protein; AhR Aryl hydrocarbon receptor; ASD Autism spectrum disorder; BBB Blood-brain barrier; BDNF Brain-derived neurotrophic factor; CNS Central nervous system; GABA ɣ-aminobutyric acid; GF Germ-free; MIA Maternal immune activation; SCFA Short-chain fatty acid; 3M-4-TMAB 3-methyl-4-(trimethylammonio)butanoate; 4-TMAP 4-(trimethylammonio)pentanoate; TMA(O) Trimethylamine(-N-oxide); TUDCA Tauroursodeoxycholic acid; ZO Zonula occludens proteins.

Entities:  

Keywords:  Gut microbiota; gut-brain axis; metabolism; metabolites; short-chain fatty acids

Mesh:

Substances:

Year:  2022        PMID: 35903003      PMCID: PMC9341364          DOI: 10.1080/19490976.2022.2102878

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


Introduction

The circulating metabolome is influenced by factors including nutrition, health status, and the gut microbiota composition.[1] Further, it is possible to predict the blood metabolome through the collection of nutritional, clinical, and microbial data highlighting the host-gut microbiota crosstalk.[1-3] As the tight relationship between gut microbiota composition and circulating metabolome has become evident, it is essential to focus on the concomitant evaluation of nutritional intake and the clinical profile alongside microbiota composition. The central nervous system (CNS) and the intestine form a multifaceted, bidirectional communication network where signals are conveyed by nervous, endocrine, and immune systems. In this so-called ‘gut–brain axis’, the gut microbiota signals the brain through the mentioned networks by activating sympathetic[4] and parasympathetic[5] neurons in the intestine, by educating the immune system[6] and by regulating the production of several neurotransmitters[7-9] and gut hormones.[10-13] Furthermore, bacterial metabolites are of special interest as they include known neuromodulators,[14,15] uremic toxins,[16] pro-inflammatory[17] and anti-inflammatory mediators[18,19] and molecules providing energy for host’s cellular metabolism.[20,21] Some metabolites of interest have been implicated in brain functions, such as neurodevelopment and regulation of neuroinflammation, as well as blood–brain barrier (BBB) integrity. The analysis of the circulating metabolome reflects the crosstalk between nutrition, microbiome, and host metabolism (summarized in Figure 1). Therefore, it may reveal potential biomarker candidates of health and disease, enable understanding of related metabolic processes and can be helpful in rationalizing individual responses to preventive or therapeutic interventions (Box 1). In addition, modulating certain type of neuroactive metabolites, by acting on nutrition and gut microbiota, represents an interesting strategy to prevent and treat neurologic and neuropsychiatric diseases. In this review, our focus is on the small metabolites with a mass below 1600 Da and we describe how neuroactive metabolites produced by the gut microbiota from dietary source are linked to key features of neuronal processes and dysfunction and risk of health outcomes thereafter (Table 1).
Figure 1.

Host metabolic homeostasis and neurological impact.

Table 1.

Gut microbiota-associated metabolites, their biological pathway, preclinical setups, and main outcomes and associations to clinical studies. Direction of outcomes are indicated by symbols as followed; increase (↑) and decrease (↓).

Mechanism of actionCommon nameChemical formulaOriginPreclinical modelMain preclinical outcomesClinical associationReference
Neurodevelopment 
3-(3-sulfooxylphenyl) propionic acidIndoxyl sulfatePhenyl sulfatePyrocatechol sulfateC9H10O6SC8H7NO4SC6H5O4SC6H6O5SXenobiotic metabolismTryptophan metabolismXenobiotic metabolismSPF, GF and gnotobiotic C57BL/6 J miceFear extinction learning ↑Altered learning-related neuronal activityn.a[38]
4-EPSC8H10O4STyrosine metabolismC57BL/6 N MIAmiceSPF and GF C57BL/6 J miceEx vivo brain tissue culturesAnxiety-like behavior ↑Oligodendrocyte maturation ↓CNS neuronal myelination ↓Altered brain activity patternsFecal levels in ASD children ↑[39–41]
5-AVABHippuric acidImidazole propionic acidTMAOC5H11NO2C9H9NO3C6H8N2O3C3H9NOLysine metabolismXenobiotic metabolismCholine and carnitine metabolismHistidine metabolismEx vivo C57Bl/6 J mice thalamic, striatal and hypothalamic explants of axonsFetal thalamocortical axonogenesis ↑n.a[28]
5-AVATaurineC5H11NO2C2H7NO3SLysine metabolismBile acid and cysteine metabolismHumanized and GF C57BL/6 miceBTBR T+ tf/J miceRepetitive behavior ↓Social behavior ↑Anxiety-like behavior ↓n.a[42]
p-CresolC7H8OTyrosine and phenylalanine metabolismNOD miceC57BL/6 miceMouse primary oligodendrocyte culturesSocial behavior ↓Medial prefrontal cortex myelination ↓Fecal and urinary levels in ASD children ↑[16,43,44]
Acetic acidPropionic acidC2H4O2C3H6O2Dietary fiber fermentationObese C57BL/6 J mice dams and offspringSocial behavior ↑Memory scores↑Microglia maturation ↑Improved synaptic ultrastructureAltered fecal SCFA profiles in ASD children[43,45–47]
IndoleC8H7NTryptophan metabolismGF, SPF and E. coli monocolonized C57BL/6 J miceEx vivo neural progenitor and stem cell culturesNeuronal maturation ↑Neurogenesis ↑n.a[36]
Neurotransmission 
 4-aminobenzoic acidDeoxycholic acidTyramineC7H7NO2C24H40OC8H11NOFolate metabolismBile acid metabolismTyrosine metabolismSPF, GF and monocolonized C57Bl/6 J, Slc6a4 KO, Swiss Webster and Rag1 KO miceRIN14B (ATCC) cell culturesEECs stimulation ↑Serotonin biosynthesis by EECs ↑n.a[9]
 p-CresolC7H8OTyrosine and phenylalanine metabolismChronic (p.o.) or acute (iv, ip) administration to Wistar rats and C57BL/6 J or BTBR T+ tf/J miceAltered brain dopamine metabolismAnxiety-like behavior ↑Social behavior ↓CSF levels ↑ in Alzheimer’s and Parkinson’s disease patients[48–51]
 Butyric acidIsobutyric acidIsovaleric acidNorepinephrineC4H8O2C4H8O2C5H10O2C8H11NO3Dietary fiber fermentationTyrosine/phenylalanine metabolismEx vivo C57BL/6 J mice intestinal organoids and colonic neuron culturesHEK293T (ATCC) cell culturesEECs are stimulated by microbial metabolitesSerotonin biosynthesis by EECs ↑EECs modulate primary afferent nerve fibersn.a[52]
 DopamineNorepinephrineC8H11NO2C8H11NO3Tyrosine and phenylalanine metabolismGF and SPF BALB/c miceBALB/c mice monocolonized with E. coliGut microbes transform luminal dopamine and norepinephrine into biologically active formn.a[7]
 GABAC4H9NO2Glutamic acid metabolismBALB/c mice treated with L. rhamnosus (JB-1) probioticsAltered brain GABA and glutamate/glutamine levelsAnxiety-like behavior ↓Depression-like behavior ↓Stress ↓Altered GABA and glutamate in postmortem brains of persons with history of heavy alcohol use[5,14,53,54]
 HistaminePhenethylamineC5H9N3C8H11NPhenylalanine and histidine metabolismC57Bl/6 mice monocolonized with M. morganii HEK293 cell culturesM. morganii strains generate trace amines activating dopamine- and histamine-receptorsMicrobial histidine decarboxylase genes are enriched in patients with Chron’s disease[15]
 IndoleC8H7NTryptophan metabolismF344 rats monocolonized with E.coliAcute (i.p.) administration to F344 ratsMouse EEC culturesAcute GLP-1 secretion from EECs ↑Anxiety-like behavior ↑Helplessness ↑n.a[55,56]
 IndoleIndole-3-aldehydeC8H7NC9H7NOTryptophan metabolismHEK-293 T mammalian cell culturesEx vivo human and mouse small intestine tissue sectionsActivation of EECs via TRP1 receptor ↑Serotonin biosynthesis by EECs ↑Indole derivatives were positively associated with memory scores[57,58]
 Kynurenic acidC10H7NO3Tryptophan metabolismKynurenin aminotransferase II KO miceAcute (i.c.v.) administration to Sprague-Dawley or Long Evans ratsBrain glutamate levels ↑ by limiting brain kynurenic acid supplyLearning ↓Memory scores ↓Decreased plasma tryptophan and kynurenic acid levels in patients with depressionCognitive functions negatively correlated to plasma kynurenine/tryptophan ratio[59–64]
 LactateC3H6O3Dietary fiber fermentationHooded rats treated with Lactobacillus- and Bifidobacterium probioticsC57BL/6NTac mice monocolonized with Lactobacillus strainsPlasma and brain lactate ↑GABA expression and signaling ↑Memory, learning and neuroplasticity ↑n.a[20,65,66]
 Pipecolic acidC6H11NO2Lysine metabolismGF and SPF BALB/c miceLevels of pipecolic acid in the cerebrum ↑ in the presence of microbiotan.a[67]
 SerotoninC10H12N2OTryptophan metabolismLactobacillus and Streptococcus culturesIn vitro production of biogenic amines, including serotoninCirculating levels decrease in substance use disorders[68–70]
 TryptamineC10H12N2Tryptophan metabolismHumanized or B. thetaiotaomicron monocolonized Swiss Webster, 129/Sv and 5-HT4R KO miceColonic organoidsActivation of colonic serotonin receptor 4 ↑Colonic secretion ↑n.a[71]
Modulation of BBB integrity 
p-Cresol glucuronideC13H16O7Tyrosine metabolismAcute (i.p.) administration to C57BI/6 miceHuman CMEC/D3 culturesBBB permeability ↓LPS-stimulated BBB permeability↓n.a[72]
Acetic acidPropionic acidC2H4O2C3H6O2Dietary fiber fermentationC57BL/6 J mice monocolonized with B. thetaiotaomicronBBB permeability ↓Tight junction protein expression ↑n.a[73]
Butyric acidC4H8O2Dietary fiber fermentationC57BL/6 J mice monocolonized with C. tyrobutyricumGF and SPF C57BL/6 J, BALB/c and NMRI miceAcute (ip) administration to C57BL/6 TBI miceBBB permeability ↓Tight junction protein expression ↑Histone acetylation ↑Neurological deficits ↓n.a[73,74]
Deoxycholic acidC24H40O4Bile acid metabolismAcute (i.v.) administration to sham or BDL-operated Sprague Dawley ratsRat BMEC culturesImpairments in tight junction integrityPhosporylation of occludin ↑Serum levels associated with cognitive decline and cerebrospinal fluid t-tau aggregation in Alzheimer’s disease patients[75–77]
Propionic acidC3H6O2Dietary fiber fermentationHuman postmortem brain endothelium and CMEC/D3 cell culturesOxidative stress ↓LPS-stimulated BBB permeability ↓n.a[78]
TMAC3H9NCholine and carnitine metabolismC57BL/6 J miceHuman CMEC/D3 culturesImpairments in barrier integrityCytoskeleton disruption and metabolic stress ↑n.a[27]
TMAOC3H9NOCholine and carnitine metabolismChronic (i.p.) and acute (i.p.) administration to C57Bl/6 J miceHuman CMEC/D3 culturesImproved barrier integrityAstrocyte and microglial function ↑Cerebrospinal fluid levels ↑ in Alzheimer’s disease patients and associated with markers of Alzheimer’s disease[27,79]
Ursodeoxycholic acidC24H40O4Bile acid metabolismHuman BMEC culturesImproved barrier integrityEndothelial cell apoptosis ↓Serum and postmortem brain levels ↑ in Alzheimer’s disease patients[76,80,81]
NeuroinflammationAcetic acidC2H4O2Dietary fiber fermentationChronic (p.o.) administration to GF and SPF C57BL/6 or 5× FAD micePrimary glia cell culturesEx vivo isolated mice microgliaMicroglial metabolism ↑Microglia maturation ↑Aβ plaque deposition ↑ in SPF mice but not in GF micen/a[82]
 Acetic acidButyric acidPropionic acidC2H4O2C4H8O2C3H6O2Dietary fiber fermentationChronic (p.o.) administration to GF C57BL/6 miceChronic (p.o.) administration to surgically or sham-treated Sprague-Dawley rat model of CCHPrimary glia cell culturesex vivo brain endothelial cell culturesChronic (p.o.) administration to GF or SPF Thy1-αSyn and GF APPPS1 miceMicroglial activity ↑Microglia maturation ↑Neuroinflammation, cognitive decline and depressive-like behavior ↓ rat model ofCCHα-syn aggregation ↑ in genetically predisposed SPF miceAβ plaque deposition ↑ in genetically predisposed GF miceBrain amyloid load positively associated with plasma acetic acid and inversely associated with plasma butyric acid in patients with cognitive complaints[83–87]
 Dihydrocaffeic acidC9H10O4Xenobiotic metabolismChronic (p.o.) administration to CD45.2+ C57BL/6 miceMice PBMC and neuron tissue culturesPro-inflammatory cytokine production ↓n.a[88]
 Indoxyl sulfateC8H7NO4STryptophan metabolismAcute (i.p.) administration to C57BL/6 miceChronic (p.o.) administration to Albino Wistar ratsEx vivo rat and mice glial cell culturesOxidative stress ↑Pro-inflammatory cytokine production ↑Locomotor activity ↑Spatial memory ↓Apathic behavior ↑CSF levels ↑ in patients with Parkinson’s diseaseUrinary levels positively associated to recurrent depressive symptoms[17,51,89,90]
 IndoleIndole-3-aldehydeIndolepropionic acidIndoxyl sulfateC8H7NOC9H7NOC11H11NO2C8H7NO4STryptophan metabolismC57BL/6 J EAE and CX3CR1-AHR miceEx vivo C57BL/6 J mice microglia and astrocyte cell culturesPrimary human microglia, brain and fetal astrocyte culturesType 1-interferon signaling ↓EAE disease scores ↓Pro-inflammatory cytokine expression ↓Serum AhR activating tryptophan metabolites ↓ in patients with multiple sclerosis[32,91]
 N[6]-carboxymethyllysineC8H16N2O4Lysine metabolismChronic (i.p. or p.o.) administration to SPF and GF C57BL/6 miceHuman cortical tissue and mice brain preparationsBone marrow-derived macrophage culturesOxidative stress in microglia ↑Microglial dysfunction ↑Associated with oxidative stress in brain tissue of elderly and patients with Alzheimer’s disease and/or diabetes mellitus[92–94]
 Propionic acidC3H6O2Dietary fiber fermentationAcute (i.c.v or i.v.) administration to Western albino, Long-Evans, seizure-prone or seizure-resistant ratsChronic (p.o.) administration to C57BL/6 EAE miceEx vivo mice Treg-cell culturesAstrogliosis and microglial activity ↓Hyperactivity ↑Social behavior ↓Inflammatory cytokines and oxidative stress ↑Treg-cell differentiation ↑CNS autoimmunity ↑n.a95–100
 TMAOC3H9NOCholine and carnitine metabolismChronic (p.o.) administration to surgically or sham treated F344× BN F1 ratsHippocampus oxidative stress ↑Neuroinflammation ↓Postoperative cognitive decline ↑Positive and inverse associations with Parkinson’s or Alzheimer’s diseases[101–105]
 Urolithin AC13H8O4Xenobiotic metabolismChronic (p.o.) administration to C57BL/6 EAE miceEx vivo C57BL/6 mice CNS mononuclear and dendritic cell culturesEx vivo 2D2 TCR mice Th17 cell culturesMurine BV-2 microglia cell culturesSPF mice model of ischemic strokePro-inflammatory cytokine gene expression ↓Microglia, dendritic and T-cell activation ↓Neuroinflammation ↓Neuronal apoptosis ↓n.a[93,94,106–108]
Neuronal energy metabolism       
3M-4-TMAB4-TMAPC8H18NO2C8H18NO2Carnitine metabolismGF and SPF C57BL/6 J micePrimary murine CNS white matter cell cultureFatty acid oxidation in CNS white matter tissue ↓n.a[109]
Acetic acidButyric acidIndolepropionic acidPropionic acidTUDCAC2H4O2C4H8O2C11H11NO2C3H6O2C26H45NO6SDietary fiberfermentationTryptophan metabolismDietary fiber fermentationBile acid metabolismChronic (p.o. or i.p.) administration to db/db miceImproved cognitive functionsImproved mitochondrial functionMitochondrial biogenesis and function ↑n.a[110]
Butyric acidPropionic acidC4H8O2C3H6O2Dietary fiber fermentationChronic (i.c.v.) administration to Long-Evans ratsLocomotor activity ↑Altered brain fatty acid profilesn.a[111]
Butyric acidC4H8O2Dietary fiber fermentationNeuroblastoma or lymphoplastoid cell cultures derived from ASD malesImproved mitochondrial functionMitochondrial gene expression ↑n.a[112]
EthanolC2H5OHEnergy metabolismSPF or humanized C57BL/6 J miceDepression-like behavior ↑Circulating β-hydroxybutyrate ↓Social behavior ↓Microbial ethanol ↑ together with β-hydroxybutyrate ↓ in alcohol-dependent subject with behavioral alterations[113]
LactateC3H6O3Energy metabolismChronic (p.o.) administration to CC042 miceC57BL/6NTac mice monocolonized with Lactobacillus speciesExercised or acute (i.p.) administration to C57BL/6 miceLong-term memory formation ↑Hippocampus GABA ↑Learning ↑Hippocampus BDNF ↑n.a[65,66,114]
Indolepropionic acidC11H11NO2Tryptophan metabolismMice neuro2a-APPsw cell culturesRestoration of cell respiratory rateReactive oxygen species ↓n.a[115]
Neuroprotection 
3-(3′-hydroxyphenyl) propionic acid3-hydroxybenzoic acidC9H10O3C7H6O3Xenobiotic metabolismChronic (p.o.) administration to Sprague-Dawley ratsSynthetic Aβ preparationsAβ plaque deposition ↑Neuroplasticity ↑n.a[116]
ErgothioneineC9H15N3O2SHistidine metabolismChronic (p.o.) administration to stressed Sprague Dawley rats or Aβ-injected C57BL/6 miceIntracerebral oxidative stress ↓Aβ plaque deposition ↓Depression-like behavior ↓Social behavior ↑Plasma levels ↓ in patients with mild cognitive impairment or Parkinson’s disease[117,118]
Ferulic acidC10H10O4Xenobiotic metabolismRat pheochromocytoma cell culturesChronic (p.o.) administration corticosterone-treated Swiss mice, PSAPP mice or Sprague-Dawley rats with acute ischemiaOxidative stress ↓Aβ plaque deposition ↓Neuronal apoptosis ↓Depression-like behavior ↓n.a[18,119,120]
Indolepropionic acidC11H11NO2Tryptophan metabolismSK-N-SH human neuroblastoma cell culturesE-18 fetal rat primary neuron cell culturesNeuronal apoptosis ↓Oxidative stress ↓n.a[121]
MenadioneMenaquinonePhylloquinoneC11H8O2C31H40O2C31H46O2Energy metabolismα-Synuclein fibril preparationsα-syn aggregation ↓n.a[122]
TUDCAC26H45NO6SBile acid metabolismChronic (p.o.) administration to APPPS1 miceAβ plaque deposition ↓Neuronal degeneration ↓n.a[123]

Abbreviations: 3 -M-4-TMAB, 3-methyl-4-(trimethylammonio)butanoate; 4-EPS, 4-ethylphenylsulfate;; 4-TMAP, 4-(trimethylammonio)pentanoate: 5-AVA(B), 5-aminovaleric acid (betaine); Aβ, amyloid beta protein; AD, Alzheimer’s disease; AhR, aryl hydrocarbon receptor; ASD, autism spectrum disorder; BDL, bile duct ligation; BMEC, brain microvascular endothelial cells; CCH, chronic cerebral hypoperfusion; CNS, central nervous system; EAE, experimental autoimmune encephalomyelitis; EEC, enteroendocrine cell; GABA, γ-aminobutyric acid; GF, germ-free; I.C.V, intracerebroventricular; I.P., intraperitoneal; I.V., intravenous; MIA, maternal immune activation; NOD, nonobese diabetic; PBMC, peripheral blood mononuclear cell; P.O., per os; SCFA, short-chain fatty acid; SPF, specific-pathogen free; TBI, traumatic brain injury; TMA(O), trimethylamine(-N-oxide); TUDCA, tauroursodeoxycholic acid.

Host metabolic homeostasis and neurological impact. Gut microbiota-associated metabolites, their biological pathway, preclinical setups, and main outcomes and associations to clinical studies. Direction of outcomes are indicated by symbols as followed; increase (↑) and decrease (↓). Abbreviations: 3 -M-4-TMAB, 3-methyl-4-(trimethylammonio)butanoate; 4-EPS, 4-ethylphenylsulfate;; 4-TMAP, 4-(trimethylammonio)pentanoate: 5-AVA(B), 5-aminovaleric acid (betaine); Aβ, amyloid beta protein; AD, Alzheimer’s disease; AhR, aryl hydrocarbon receptor; ASD, autism spectrum disorder; BDL, bile duct ligation; BMEC, brain microvascular endothelial cells; CCH, chronic cerebral hypoperfusion; CNS, central nervous system; EAE, experimental autoimmune encephalomyelitis; EEC, enteroendocrine cell; GABA, γ-aminobutyric acid; GF, germ-free; I.C.V, intracerebroventricular; I.P., intraperitoneal; I.V., intravenous; MIA, maternal immune activation; NOD, nonobese diabetic; PBMC, peripheral blood mononuclear cell; P.O., per os; SCFA, short-chain fatty acid; SPF, specific-pathogen free; TBI, traumatic brain injury; TMA(O), trimethylamine(-N-oxide); TUDCA, tauroursodeoxycholic acid.

Microbiota-related metabolites modulating brain function

Neurodevelopment

Mouse models devoid of gut microbiota, the germ-free (GF) mice, elicit characteristics supporting the view that the gut microbiota is crucial for the normal brain development and behavior.[124,125] Desbonnet et al.[126] showed that despite of normal gut microbiota at birth, mice treated with antibiotics in the early weeks of life display cognitive and behavioral alterations later in life. Given that the neurodevelopmental processes are initiated in the prenatal phases, maternal microbiota, and related molecules may influence fetal development as observed in the field of early immune development.[127-129] The maternal immune activation (MIA) mice model of autism spectrum disorder (ASD) was used in the pivotal work by Hsiao et al.[39] to study how the maternal microbiota influences offspring’s brain development. The postnatal serum metabolomic analyses revealed that the level of 4-ethylphenylsulfate (4-EPS), a tyrosine-derivative, was 46-fold higher in MIA offspring compared to control offspring. Postnatal treatment with the human commensal Bacteroides fragilis improved several features of ASD in MIA offspring and restored the 4-EPS levels which were explained by the improvements in intestinal permeability and thus decreased translocation of 4-EPS to the circulation. The microbiota modulates the production of 4-EPS as it was nearly undetectable in GF compared to specific pathogen-free mice. Additionally, administration of 4-EPS to naive wild-type mice at postnatal weeks 3–6 induced anxiety-like behavior similar to MIA offspring. The biosynthetic pathway and mechanisms behind the detrimental effects of 4-EPS were lately elucidated by Needham et al.[40] showing that 4-EPS interfered with oligodendrocyte maturation, myelination, and brain activity patterns in brain areas of the limbic system. p-Cresol, a tyrosine-derivative and a metabolite differing from 4-EPS by the methyl substitution in the phenyl ring instead of ethyl, has also been directly associated with neurodevelopmental disorders. Social behavior impairments were triggered by daily gavages of vehicle but not with antibiotics and a fecal microbiota transplant from vehicle-treated mice to recipient mice transferred the behavioral traits.[16] The recipients also displayed decreased medial prefrontal cortex myelination and high levels of circulating p-cresol. Interestingly, some microbial products may also protect from ASD behavioral features as reported by Sharon et al.[42] in GF mice offspring colonized by human ASD microbiota. Compared to mice with microbiota from normally developing donors, the ASD mice had significantly lower levels of 5-aminovaleric acid (5-AVA) and taurine, products of amino acid metabolism by the microbiota. Moreover, administration of these metabolites during the prenatal period or before reaching postnatal age of 4 weeks ameliorated ASD-like behavior in the offspring. Maternal obesity-induced cognitive and social deficits in the offspring were also reversed by post-weaning supplementation of short-chain fatty acids (SCFAs) acetic and propionic acid together with improvements in synaptic ultrastructure and microglial maturation in the hippocampus.[45] Microbiota signaling during a critical development period was also required for fear extinction learning and related neuronal plasticity in mice.[38] Moreover, multi-site metabolomics revealed four phenolic derivatives and sulfates: phenyl sulfate, pyrocatechol sulfate, 3-(3-sulfooxyphenyl)propanoic acid and indoxyl sulfate, as potential microbiota-derived signaling molecules in the context of fear learning and behavior. In a recent work, Vuong et al.[28] demonstrated that maternal microbiota has a crucial role in fetal thalamocortical axonogenesis, the axonal branching connecting thalamus to the cortical areas of the brain. Subsequently, absence or depletion of maternal microbiota impaired the neurobehavioral responses of the adult offspring. Colonization by Clostridia-dominant bacteria was sufficient to restore fetal axonogenesis, and the effect was mediated through selected bacteria-derived metabolites. TMAO, 5-AVA, 5-aminovaleric acid betaine (5-AVAB), imidazolepropionic acid, and hippuric acid were found to promote axonogenesis both in vitro and in vivo, in the absence of live bacteria.[28] Although the microbiota-dependency and maternal translocation of the named metabolites to the fetus have been reported in several works,[67,130-132] their contribution to host neurodevelopment is a novel finding likely to spark intensive further research. Additionally, the neurogenic properties of metabolites may not be limited to early life since indole, a tryptophan metabolite, was found to increase neurogenesis in the hippocampus of adult mice.[36] The effect mediated by aryl hydrocarbon receptor (AhR) was specific to indole because another AhR ligand and also a tryptophan-derivative, kynurenine, did not induce any changes in neurogenesis ex vivo. Studies on the relationship between human neurodevelopment and gut microbiota metabolites rely on limited number of cross-sectional and associative works done mainly in children with ASD. These children display deviations in a range of sulfates when compared to normally developing children. For instance, the elevation of 4-EPS was observed in plasma[41] in line with earlier findings of the increase in urinary and fecal p-cresol sulfate[43,44] in children with ASD. De Angelis et al.[43] also noted elevations in the fecal indole levels among the ASD group. Results on differences between fecal SCFA concentrations, fermentation products of dietary fiber, in children diagnosed with ASD compared to normally developing children have been inconclusive as increased,[46] decreased,[43,47,133] and comparable[134,135] concentrations have been reported. Human studies initiated at the early stages of life with long follow-up times and application of multi-omics approaches are essential to understand how the host–microbe interactions influence neurodevelopment. Efforts such as the first pilot studies employing fecal microbiota transplantation in children[136] and infants[137] open new possibilities to study whether there are long-term effects on neurodevelopment or behavior in early-life interventions targeting the gut microbiota composition and functionality.

Neurotransmission

In addition to the production of neurotransmitters, gut microbiota, and its metabolites can influence host’s central metabolism of neuroactive compounds.[130] The most robust examples of gut bacteria-derived neurotransmitters are aromatic amino acid derivatives dopamine and norepinephrine[138] and glutamate derivative γ-aminobutyric acid (GABA).[14] In the gut lumen, microbiota significantly contributes via the activity of β-glucuronidase to the levels of free dopamine and norepinephrine.[7] However, this may not directly translate into increased brain levels of dopamine as GF mice had higher concentration of dopamine in cerebrum compared to conventionalized mice.[67] Also, inconsistent tissue-specific variation has been observed in GABA levels as conventionalized mice exhibit substantially higher levels of GABA within the colon and the blood but not in the brain in relation to their GF counterparts.[67,139] Kynurenic acid, a tryptophan metabolite, serves as a modulator of extracellular glutamate as it reduces glutamate levels that participate in the glutamatergic signaling in the hippocampus.[59,60] Consequently, increasing glutamate levels through limiting hippocampal kynurenic supply enhanced cognitive abilities and memory in rats and mice.[59-61] Deviations in the CNS and peripheral glutamate-glutamine-GABA metabolism were depicted by elevated glutamine and GABA and decreased glutamate in hippocampus while serum GABA remained unchanged in mice after fecal microbiota transplantation from schizophrenic patients.[140] However, a 4-week treatment with Lactobacillus rhamnosus increased glutamate, GABA and N-acetyl aspartate concentrations in mice brains, returning to baseline after 4-weeks of treatment cessation.55 L. rhamnosus treatment was also shown to alter brain GABA receptor expression in a regionally dependent manner and reduce stress-induced corticosterone and anxiety- and depression-like behavior in mice.[5] These effects occurred through vagal communication as vagotomy prevented such changes suggesting a peripheral, gut-centered route to modulate brain functions and behavior. Over 90% of serotonin in the body is produced by the enterochromaffin cells of the gut synthesizing serotonin from tryptophan, a process where gut commensals have an important regulatory role.[8,9] Tyramine, deoxycholic acid, and 4-aminobenzoic acid were found to stimulate serotonin synthesis both in vitro and in vivo.[9] Moreover, microbiota-associated metabolites like norepinephrine, indole, indole-3-aldehyde, isovaleric acid, butyric acid, and isobutyric acid stimulate enterochromaffin cells to release serotonin, which then engages with serotonin-receptor-expressing nerve fibers.[52,57] In addition, some gut bacteria can produce serotonin but the physiological significance of this is currently unknown.[68,141] The presence of pipecolic acid in the CNS can be partially derived from the microbiota[130] and has been associated with GABA signaling and release.[142,143] Another metabolite with a plausible connection to GABA expression in the brain, hippocampus and frontal cortex more precisely, is lactate.[20,65] Lactate can also induce brain-derived neurotrophic factor (BDNF) expression in the hippocampus through the upregulation of Sirtuin1 deacetylase.[66] Together, these studies show that lactate affects neural plasticity and has a beneficial effect on learning and memory in mice. SCFAs, particularly butyric acid, may also have additional regulatory effects on the production of neurotrophic factors, such as BDNF, signal the brain via vagal nerve and induce biosynthesis of neurotransmitters in the CNS.[21] Individual administration of SCFAs butyric, acetic, and propionic acid ameliorated stress-responsivity, anxiety- and depressive-like behavior in mice concomitant with downregulation of several hypothalamic genes involved in stress signaling.[144] Metabolites may also have negative neuromodulatory activities: administration of p-cresol has been observed to modulate oxytocinergic and opioidergic systems, dopamine turnover and receptor activity in specific brain regions while eliciting negative traits in social and anxiety-like behaviors in mice or rats.[48-50] Such findings may partially explain the harmful effects of p-cresol on neurodevelopment. Selected gut microbial species can also produce neurotransmitter receptor agonists or induce local synthesis of neuroactive mediators. Phenylethylamine is a full dopamine receptor agonist produced by Morganella morganii strains and capable of crossing the BBB.[15] The previously described 5-AVA and taurine may also act as weak GABAA receptor agonists.[42] Tryptamine is found in low concentrations in the brain, produced by selected bacterial strains of the Clostridium sporogenes and Ruminococcus gnavus species[145] and acts through epithelial serotonin-receptor (5-HT4), a G-protein coupled receptor, increasing colonic secretion and gut transit time without affecting the colonic serotonin excretion.[71] Indole-derivatives accumulate in the brain;[55,146] overproduction of indole, whether acute or chronic, triggered anxiety-like behavior and stimulated vagal afferent fibers in the intestinal mucosa in rats.[55] However, in mice, the chronic overproduction of indole had adverse effects on behavior only when mice were subjected to chronic stress.[146] Controversially, increased indoles, especially indoleacetic acid, were linked with reduced anxiety-like behavior in mice receiving fecal microbiota transplantation from patients with irritable bowel syndrome and subsequently treated by probiotic strain Saccharomyces boulardii.[147] Indole also promotes short-term glucagon-like-peptide-1 release from colonic L cells,[56] while SCFAs induce the secretion of both glucagon-like-peptide-1 and peptide YY from the enteroendocrine cells and leptin from adipocytes, all hormones participating in the food intake regulation signaling in the central and peripheral nervous system.10−13 These observations described above suggest that neurotransmitters, neurotransmitter receptor agonists and other neuroactive mediators produced by the gut microbiota signal the brain via the peripheral nervous system and can alter the synthesis pathways of neurotransmitters in the brain. While the findings from clinical studies are associative and focus on plasma metabolites, they support the preclinical results, to some extent. Decreased circulating levels of serotonin are a classical sign of related brain disorders like depression and alcohol use disorder.[69,148,149] For example, reduced circulating serotonin levels precede future diagnosis of alcohol use-related diseases even when baseline alcohol drinking is accounted for.[70] However, the regulation of circulating serotonin levels is multifaceted and influenced by external factors, such as diet.[148,150] The situation of serotonin system in the brain is even more complex, since serotonin is an important modulator of neurotransmission and therefore the brain levels are controlled differently to the levels in the blood.[148,149] The tryptophan metabolism, especially increased catabolism of tryptophan through the kynurenine pathway, has been linked with depression and ASD in humans.[151] Arnoriaga-Rodríguez et al.[58] showed that while tyrosine and tryptophan correlated positively with memory scores, the associations between their catabolites and memory scores were only evident in the obese but not in lean subjects and bacterial functions related to tryptophan and phenylalanine metabolism were negatively correlated with performance in memory tests. Cognitive functions such as learning were also negatively correlated with plasma kynurenine/tryptophan ratio in female subjects with medically diagnosed depression.[62] A meta-analysis of the peripheral blood metabolites in medically diagnosed patients showed consistent reduction of tryptophan and kynurenic acid relative to healthy controls.[63] Very recent data associated urinary excretion of indoxyl sulfate, the major final metabolite of indole, to recurrent depressive symptoms in female patients.[89] Administration of the so-called psychobiotics – probiotic strains that could benefit mental health – reduced plasma kynurenine level while improving cognitive functions[64] and increased gene expressions related to the tryptophan-serotonin metabolism in stressed adults.[152] Valles-Colomer et al.[141] found a positive correlation between the mental quality of life score and the microbial pathway synthesizing a dopamine metabolite 3, 4-dihydroxyphenylacetic acid. However, 3, 4-dihydroxyphenylacetic acid has also been proposed as a biomarker of neurodegenerative disorders, mainly Alzheimer’s disease.[153]

Blood–brain barrier integrity

The BBB is a semipermeable diffusion barrier separating circulating blood and brain regions, apart from the circumventricular organs.[154] Together with astrocytes, pericytes, microglia, neurons, and extracellular matrix, the brain microvascular endothelial cells connected by tight junction proteins form a dynamic cellular system maintaining brain homeostasis. In its neuroprotective role, the barrier restricts pathogens, peripheral immune factors, and large molecules from entering the brain, also limiting the passage of gut metabolites to the CNS. Gut microbiota is vital for the normal barrier function during pre- and postnatal periods as BBB permeability was increased in GF compared to specific pathogen-free mice.[73] Moreover, colonizing GF mice with butyric acid-producing C. tyrobutyricum or acetic and propionic acid-producing Bacteroides thetaiomicron or oral administration of sodium butyrate restored the BBB permeability to the status seen in the controls. The administration of sodium butyrate increased the expression of occludin in the frontal cortex and hippocampus and increased brain histone deacetylation, which was also detected in C. tyrobutyricum inoculated GF mice. Accordingly, in a mice model of traumatic brain injury characterized by severe BBB disruption, a single intraperitoneal injection of sodium butyrate reproduced the partially alleviating effects on BBB integrity through increased expression of zonula occludens-1 (ZO) protein and occludin.[74] Addition of a physiologically relevant dose of propionic acid to an in vitro model of human BBB showed the modulatory effect being independent of tight junction protein expression.[78] Instead, propionate promoted BBB integrity by mitigating oxidative and pro-inflammatory pathways and by reducing the expression of a specific efflux transporter low-density lipoprotein receptor-related protein 1. High affinity monocarboxylate transporters facilitate the translocation of SCFAs and are abundantly expressed on the endothelial cells, neurons, and astrocytes.[21] Furthermore, SCFA receptor FFAR3 is widely expressed in the sympathetic nervous system and has been found in rat – but not in mice – brain tissue. However, contrary to the verdicts from in vitro and rat studies, the uptake of SCFAs into the CNS seems to be nominal in humans as peripheral levels are in µmolar range compared to the picomolar range observed in the brain tissue.[21] This implies that the effects of SCFAs may rather result from peripheral signaling instead of direct uptake to the brain as seen in animal models. Aside from the SCFAs, secondary bile acids deoxycholic acid and ursodeoxycholic acid may modulate BBB integrity. Injection of deoxycholic acid in rats increased BBB permeability demonstrated by colorimetric assay and albumin immunoreactivity.[75] The mechanism was mediated by disruption of the tight junction proteins occludin and ZO-1 and ZO-2. On contrary, in an in vitro model mimicking the effect of severe hyperbilirubinemia on BBB, ursodeoxycholic acid partially protected endothelial cells from apoptosis and partially restored the barrier integrity.[80] Lastly, recent data sustain that trimethylamine (TMA), a metabolite derived from dietary choline, betaine, and L-carnitine had a dose-dependent detrimental impact on the barrier integrity in an in vitro BBB model by impairing the actin cytoskeleton and inducing metabolic stress.[27] Interestingly, the oxidized form of TMA, TMAO, improved the barrier integrity both in vitro and in vivo when physiologically relevant doses were used. Systemic administration of TMAO to wild-type male mice protected from lipopolysaccharide-induced damages to the BBB function and prevented the loss of performance in the working memory test. Similarly, a host–gut co-metabolite p-cresol glucuronide improved BBB integrity in vivo and prevented lipopolysaccharide-induced permeabilization of the BBB in vitro by acting as a Toll-like receptor 4 antagonist.[72] Selectivity of the BBB restricts the passage of most metabolites to the brain although transporters, diffusion, or transcytosis could facilitate crossing of the BBB of certain compounds (Figure 2) corroborating the evidence from GF mice.[28,54,131] Nevertheless, microbial metabolites such as 5-AVAB, TMAO, p-cresol sulfate, and hippuric acid among others have been found in the human brain.[54] In addition to translocation to the brain, the metabolites could alter barrier function to some extent but the physiological significance of this in humans is yet to be determined. In Alzheimer’s disease patients the increase in microbially produced deoxycholic acid and its taurine or glycine conjugated forms in the serum had a strong association with cognitive impairment[76] and cerebrospinal fluid t-tau aggregation.[77] A gradual increase in the plasma lithocholic acid along the disease progression over follow up time of 9 years has also been recorded.[155] In the brain, the concentrations of taurolithocholic, 3-dehydrochenodeoxycholic, and ursodeoxycholic acid were significantly higher in relation to controls.[81] The findings from genome-scale reconstructions suggested that the potential to synthetize these molecules is limited to a small number of bacteria species[156] that could be the focus of future studies to scrutinize the role of bacterial bile acid transformation and BBB integrity in neurodegenerative diseases.
Figure 2.

The integrity and selectivity of the blood–brain barrier in terms of microbial metabolites.

The integrity and selectivity of the blood–brain barrier in terms of microbial metabolites.

Neuroinflammation

The inflammatory responses of the CNS to infection, non-sterile inflammation (brain lesion, traumatic brain injury, etc.), pathological conditions, obesity/metabolic diseases (meta-inflammation), and aging (inflammaging) are characterized by the production of pro-inflammatory cytokines, reactive oxygen species, and chemokines by invading immune cells and/or resident brain cells.[157,158] However, depending on the magnitude and extent of neuroinflammation, and the phagocytic capacity of microglia, the resident brain macrophages, the outcomes may support brain return to homeostasis or elicit neuropathological processes, such as the one associated with neurodegenerative diseases and traumatic injuries.[159] Studies in GF mice have indicated that microbiota has an integral role in the modulation of host immune development, both locally in the intestine and in the CNS.[83,160-162] Bacterial components are recognized by the host immune system and this constant crosstalk maintains the immune homeostasis and educates the system to discriminate pathogens from symbionts. Nevertheless, bacterial metabolites also contribute to this crosstalk and can modulate inflammation, including in the brain.[162] For example, TMAO administration exacerbated postoperative cognitive dysfunction in rodents, possibly through its effect on increased microglia activation and neuroinflammation.[101,102] In aged mice, the microbiota-related TMAO and N[6]-carboxymethyllysine were upregulated in the serum and brain tissue, but only N[6]-carboxymethyllysine induced microglial dysfunction by interfering with mitochondrial function and increasing oxidative stress.[92] Contrary to aged mice, such effects were evident in young mice only after intraperitoneal, but not oral administration. The assessment of gut permeability revealed age-dependent changes in microbiota composition facilitating the disruption of gut barrier properties and concomitant translocation to the circulation and brain. On the other hand, malformed microglia in the absence of microbiota could be restored by administration of gut microbial metabolites, such as SCFAs that reinstated the T cell balance in the CNS.[83,95] Such findings indicate that SCFAs can participate in the immune cell maturation and homeostasis in the CNS via peripheral signaling. Recent data further indicate that SCFAs (as a mix of butyric, propionic, and acetic acid) increase microglial recruitment and reactivity.[84] Also, reinstating the SCFA-producing floras or administration of SCFAs inhibited hippocampal neuroinflammation and neuronal apoptosis, thus ameliorating cognitive decline and depressive-like behavior in a rat model of chronic cerebral hypoperfusion.[85] Controversially, propionic acid alone has been linked with CNS oxidative stress, astrogliosis, hyperactivity, and social behavior abnormalities in a series of rat models of ASD.[96-100] Interestingly, SCFAs had no effect on the α-synuclein aggregation in vitro, but induced aggregation in selected brain regions and promoted motor deficits in an in vivo genetic model of Parkinson’s disease.[86] Correspondingly, SCFAs were found to increase amyloid beta protein (Aβ) deposition and microglia derived ApoE expression in an in vivo model of Alzheimer’s disease but not in vitro.[84] Acetate induced GF mice’s microglia maturation and restored defects in the microglial mitochondrial metabolism but decreased microglia phagocytosis in an mice model of Alzheimer’s disease resulting in increased Aβ deposition.[82] SCFAs could be of high interest in regulating microglia activity through the maintenance of physiological neuroimmune activity and through their polarization toward a pro-resolutive phenotype in neurodegenerative diseases. Pro-inflammatory cytokines are well-known contributors to the pathophysiology of mood disorders through their action in the brain.[163,164] Dihydrocaffeic acid was identified as a potential suppressor of peripheral IL-6 in a mice model of stress-induced depression.[88] This compound with antioxidant properties is a polyphenol derivative from caffeic acid and requires the biotransformation of the gut bacteria. The mechanism behind the attenuated depression symptoms after the administration of dihydrocaffeic acid was independent of changes in the brain monoaminergic pathways. Rather, it was suggested to derive from epigenetic changes in the form of DNA methylation in genes coding IL-6 resulting in decreased pro-inflammatory cytokine expression. Tryptophan-derived metabolites are a major group of AhR activators and the significance of AhR-signaling pathway has been recently associated with intestinal immune responses and neurological signaling.[165,166] Tryptophan is catabolized through several pathways, including the kynurenine pathway, that produces intermediates with both pro- and anti-inflammatory properties, such as indoles, although their overall significance remains controversial.[167] For instance, indoxyl sulfate promoted oxidative stress and inflammation in mice primary astrocyte and mixed glial cell cultures and caused dose-dependent neuronal cell death.[17] Furthermore, single administration in vivo was followed by histological brain alterations and increase in inflammatory markers in mice. In rats, chronic indoxyl sulfate treatment modeling patients with chronic kidney disease resulted in behavioral alterations and impairments in spatial memory and locomotor activity.[90] Controversially, indoxyl sulfate, indolepropionic acid, and indole-3-aldehyde modulated astrocyte activation and suppressed CNS inflammation both in vitro and in vivo in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.[32,91] Furthermore, AhR was also activated by indoxyl sulfate in human astrocytes followed by a decrease in proinflammatory gene expression. Samples from individuals with multiple sclerosis suggested that AhR-dependent regulation was impaired together with reduced number of tryptophan-derived activators.[32] Such contradicting results may spur from species- or disease-related differences, intensity, and duration of indoxyl sulfate administration or currently unspecified agonistic properties. Recently, urolithin A, a gut-derived metabolite of ellagic acid, has been shown to reduce neuroinflammatory processes and microglia activation, and alleviate symptoms of experimental multiple sclerosis, through AhR.[106,107] In a mouse model of stroke, urolithin A reduced neuroinflammation and neuronal loss limiting the deficits in neurological functions.[108] A number of preclinical works suggest that SCFAs are imperative bacterial metabolites in terms of immune modulation and neuroinflammation but with their limited translocation to the brain, the suppression of neuroinflammation is likely transmitted via peripheral signaling.[21] Moreover, the detrimental effects of intracerebroventricular propionic acid imply that within the CNS, SCFAs might aggravate inflammatory responses.[96-99] However, the number of clinical studies with SCFAs is limited and results on systemic inflammation markers are inconclusive.[87,168] Bacterial metabolites that function as AhR agonists can reach the CNS and regulate inflammation, but the overall outcome is dictated by factors, such as the health status of the host and the balance between pro- and anti-inflammatory agonists.[165] For instance, Sankowski et al.[51] demonstrated in a pilot study that the cerebrospinal fluid/plasma ratios of indoxyl sulfate, TMAO, and p-cresol sulfate were 4–8 times higher in Parkinson’s disease patients than in healthy controls and their concentration in the cerebrospinal fluid was linked to a more advanced disease stage in the absence of decreased kidney function. In addition to Parkinson’s disease, TMAO-related microbial genetic pathways have been associated with Alzheimer’s disease[153] and elevated TMAO in the cerebrospinal fluid has been recorded in patients with Alzheimer’s disease,[79] in the plasma of patients with post-stroke cognitive impairment[103] in addition to inverse correlation to cognitive performance[102] in middle-aged and older humans. However, recent contradicting evidence did not support causality between TMAO and Alzheimer’s disease[104] accompanied with findings of lower plasma TMAO in Parkinson’s patients[105] compared to controls. Finally, the advanced glycation end product N[-carboxymethyllysine has been identified in brain tissue and associated with oxidative stress in elderly and patients with Alzheimer’s disease or diabetes.[93,94]

Neuronal energy metabolism

The neurons, principal component of the nervous tissue use up to 80% of the brain’s energy production to maintain the excitability of the synapses.[169] Brain cells rely mainly on glucose, although ketone bodies and lactate can be utilized flexibly to support the energy demand of the neuronal network. Astrocytes can store glucose as glycogen or metabolize it via glycolysis yielding lactate to be oxidized in neurons and this astrocyte-neuron glycogenolytic lactate production and transporting is crucial for long-term memory formation and subsequent synaptic plasticity that is not sustained by glucose delivery alone.[114] Peripherally supplied lactate can also reach the CNS since bacteria-produced lactate was identified as the source of memory enhancements in mice.[20] The lactate production in astrocytes is also entangled with the glutamine-glutamate cycle, possibly linking the observed effects to the downstream production of neurotransmitters glutamate and/or GABA, both participating in learning and memory functions.[170,171] Nevertheless, lactate itself augments neural activity as the primary energy source and the lactate receptor GPR81 is enriched in regions of cerebral neocortex, hippocampus, and the BBB highlighting its several functions in neural processes.[172,173] Fecal microbiota transplantation from subjects with alcohol use disorders to recipient mice resulted in enrichment of ethanol-producing bacterial species, reduction in lipolysis, and the supply of ketone bodies in the circulation.[113] Specifically, depletion of β-hydroxybutyrate was associated with increased inflammatory responses and decreased markers of myelination and social behavior. The latter findings were also replicated in a cohort of subjects with alcohol use disorder.[113] Moreover, ketogenic meals or administration of β-hydroxybutyrate has been shown to improve memory or cognitive performance in elderly or type 2 diabetic subjects.[174,175] Also, the GABAergic neurons can utilize β-hydroxybutyrate to produce neurotransmitters GABA and glutamate,[176] which are altered in the postmortem brains of persons with history of heavy alcohol use.[54] Recently, intermittent fasting was shown to improve cognitive function via gut–brain axis in db/db mice and simultaneously modulate brain energy metabolism in hippocampus.[110] Fasting significantly increased the plasma levels of indolepropionic acid and tauroursodeoxycholic acid (TUDCA) and fecal levels of SCFAs. Individual administrations of indolepropionic acid or TUDCA or a mixture of SCFAs acetic, propionic and butyric acid were able to reproduce the effects of fasting in cognition, hippocampal mitochondrial biogenesis, and energy metabolism-related gene expression. Previously, incubating mice brain mitochondrial preparations with indolepropionic acid supported mitochondrial function by increasing membrane potential and inhibited generation of free radicals.[177] Indolepropionic acid has also been shown to increase mitochondrial respiratory rates in amyloid precursor protein expressing neuroblastoma cell cultures.[115] On the contrary, butyric or propionic acid treatments have been associated with disturbed mitochondrial fatty acid metabolism in a rat model of ASD[111] but butyric acid alone improved mitochondrial function in lymphoblastoid cell line derived from ASD boys.[112] Recently, Hulme et al. identified two novel microbial-derived structural analogues of carnitine, 3-methyl-4-(trimethylammonio)butanoate (3M-4-TMAB), and 4-(trimethylammonio)pentanoate (4-TMAP), that were found to colocalize with carnitine in brain white matter.[109] The fatty acid oxidation in mitochondria is in part mediated by carnitine and in subsequent in vitro cell models of murine white matter the metabolites were observed to inhibit the rate of fatty acid oxidation, thus interfering with mitochondrial function. An isomer of the compounds, gut microbiota-associated compound 5-AVAB, has also been shown to limit fatty acid oxidation in mouse cardiomyocytes by interfering with carnitine transportation into the cell.[178] Impairments in mitochondrial functions are considered as independent drivers of cognitive decline observed in the aging brain, neurodegenerative disorders, and neurodegeneration caused by external exposures like alcohol.[179] Also, mitochondrial dysfunction has been associated with ASD.[180] Thus, approaches targeting and supporting brain bioenergetics should be evaluated in the future. Findings connecting microbial metabolites to brain bioenergetics are preliminary but show that certain compounds are incorporated in the neuronal energy metabolism. However, the overall impact of many of these metabolites on mitochondrial output has not been investigated in humans making their contribution to brain health uncertain.

Neuroprotection

Actions resulting in preservation or recovery of the neuronal cells, their structural network or function are defined as neuroprotective. Hence, metabolites of the gut microbiota reducing oxidative stress or aggregation of neurotoxic proteins can be considered as neuroprotective agents. In this context, metabolites that reduce inflammation or promote neurodevelopment or neurotransmission are also neuroprotective. The number of phytochemicals with suggested neuroprotective effects is considerable and here we cover only few examples of gut microbial metabolites as there are other focused articles available (for reviews, see refs.[181-183]). For instance, ferulic acid is a phytochemical associated to dietary fibers present in many plant products, released from the fiber matrix, and further metabolized by the gut microbes.[184] Ferulic acid holds neuroprotective effects by limiting neuronal cell death and improves memory deficits in a mouse model of cerebral ischemia and reperfusion injury.[18] In a mouse model of corticosterone administration-induced depression, ferulic acid ameliorated depression-like behavior and oxidative stress.[119] A microbiota-borne metabolite and a downstream product of ferulic acid, dihydroferulic acid, also exhibits neuroprotective antioxidative properties in vitro.[19] Phytochemicals have also shown potential neuroprotective properties in cell and murine models of Alzheimer’s disease where the aggregation of neurotoxic Aβ fragments were inhibited in the presence of polyphenol metabolites. For example, ferulic acid reduced hyperactivity and Alzheimer’s disease-related pathological changes in the brain while improving spatial working and reference memory in a murine model of cerebral amyloidosis.[120] Metabolites of flavonoids and phenolic acids, 3-hydroxybenzoic acid and 3-(3′-hydroxyphenyl)propionic acid, were shown to accumulate in mice brain at µM concentration following administration of grape seed polyphenol extract or red wine and inhibit the formation of Aβ aggregates in vitro.[116] In preclinical models of neurodegenerative diseases called synucleinopathies, vitamins K (phylloquinone, menaquinone, and menadione) produced by the microbiota did inhibit the aggregation of the protein α-synuclein within the neurons in vitro.[122] Ergothioneine is a histidine derivative produced by gut bacteria that is translocated to the brain and protects from oxidative stress as well as Aβ-induced cellular damage in vitro and in vivo.[117,118] Finally, TUDCA has been shown to reduce neuronal apoptosis in several other preclinical models of neurodegenerative disease such as Huntington’s, Alzheimer’s and Parkinson’s diseases and acute ischemia and interfere with Aβ production[123,185] while addition of indolepropionic acid prevented oxidative stress and neuron apoptosis in neuroblastoma cell cultures exposed to Aβ.[121] A range of gut-derived metabolites exert neuroprotective properties in in vitro and in vivo preclinical models, but convincing clinical studies are lacking. For example, administration of plant or fruit extracts to humans has improved cognitive functions and mood in various feeding trials, but these studies did not explore the effect on the metabolome.[183] Nevertheless, the accumulating number of reports showing that amino acid- and polyphenol-derivatives interfere with the formation of neurotoxic proteins, oxidative, and inflammatory cascades warrant for further clinical studies targeting patients with neurodegenerative diseases.

Enteric nervous and immune systems as pathways of communication

Enteric nervous system

Without ever reaching the circulation and brain, the microbial metabolites can begin communication toward the brain through the gastrointestinal sites of nervous and immune systems (Figure 3). The enteric nervous system is a neuronal network of sensory neurons, motor neurons, interneurons, and supporting cells such as enteric glial cells embedded in the intestinal wall throughout the gastrointestinal tract.[186] As the endings of the intrinsic primary afferent neurons are in the submucosa, the enteric nervous system is the first neuronal interface that could be directly or indirectly activated by the microbial metabolites.[187] While it can operate functions such as local motility and secretion autonomously, this component of autonomic nervous system is connected to the CNS via sympathetic and parasympathetic pathways forming a loop of gut–brain–gut signaling. The sensory information from the gut to the brain is carried by primary afferent neurons of the vagal and spinal branches of which the former have been suggested as a key transmitter of gut microbiota stimulus. Indeed, the vagus nerve is composed of up to 90% of afferent fibers and depending on the location and type of the afferent fiber, they are stimulated by neurotransmitters, gut microbial metabolites, or gut hormones.[188] Consequently, it has been shown that the vagus nerve is indirectly activated by the gut microbiota-associated metabolites such as serotonin,[57] SCFAs,[4] and indole.[55] Moreover, the vagal pathways are also linked with the hypothalamic–pituitary–adrenal axis, which is a major regulator of stress responses. Coupled with the findings that vagotomy affects brain functions[5] and vagus nerve stimulation modulates mood and behavior,[188] the enteric nervous system–vagus–brain pathway is likely one of the main mechanisms of gut–brain axis communication.
Figure 3.

Communication routes between the gut and brain.

Communication routes between the gut and brain. Other forms of indirect enteric neuron activation are the enteroendocrine signaling by colonic L cells or enterochromaffin cells. The colonic enterochromaffin cells produce the majority of the circulating serotonin in the human blood.[189] As discussed previously, several bacterial metabolites have been shown to influence the enterochromaffin cells’ serotonin synthesis.[9] Enteric neurons in the submucosa are in close proximity of the translocated serotonin from the lumen and express serotonin receptors. In addition to neuronal stimulation, serotonin might have a role in the development, maturation, and protection of the enteric nervous system.[190] Similar to enterochromaffin cells, colonic L cells are activated by microbial metabolites, such as SCFAs and secondary bile acids among others.[188] The L cells produce bioactive peptides such as GLP-1 and PYY both known for their local effects on gut motility and secretion, and central effects on food intake and feeding behavior.[191-193] The hormones released by L cells have multiple effectors, including enteric neurons and vagus nerve, that carry the signal toward CNS.[194] However, recently Bohórquez et al.[195] uncovered a neuroepithelial circuit connecting the enteroendocrine cell to sensory neurons, together referred as neuropods. This suggests that among the endocrine signaling, the enteroendocrine cells could form physical connections with the neurons as a conduit for sensory transmission activated by microbial metabolites. In theory, the microbiota’s production of neurotransmitters, for example, histamine, serotonin, or GABA, could directly engage with the enteric neurons in a paracrine manner.[194] However, it is questionable whether microbiota-derived neurotransmitters could reach enteric neurons in meaningful concentrations. The enteric neurons also express pattern recognition receptors, including the Toll-like receptors, that are activated by microbial molecules.[194] The significance of the Toll-like receptors in the physiology of the enteric nervous system has been shown in mice, where the lack of these receptors reduced gut motility and produced neuronal defects, both reversed by the administration of Toll-like receptor agonist to naïve animals.[196] Moreover, in the absence of gut microbiota, the maturation and function of enteric nervous system is compromised underlining the significance of microbial cues in normal gut physiology.[194]

Immune system

The cells of innate and adaptive immune systems in the gastrointestinal tract are the first responders to immune challenges produced by the gut microbiota.[197] Reports from GF animals have suggested that the microbiota–host immunity crosstalk, especially in the early life, is imperative for the development and modulation of the immune homeostasis.[6,160] The innate immune system detects microbial components through pattern-recognizing receptors, which are activated by microbe-associated molecular patterns.[197] As with enteric neurons, Toll-like receptors are central pattern-recognizing receptors detecting microbe-associated molecules such as lipopolysaccharides, glycolipids, or lipopeptides. Activation of the innate immune response results into a signaling cascade, increasing the production of cytokines and chemokines and the recruitment of local macrophages and dendritic cells. These cells also act as antigen-presenting cells to further trigger local adaptive immune responses facilitating the migration of circulating T- and B-lymphocytes to the site of inflammation. Apparently, some gut-derived metabolites like the SCFAs may have a regulatory role in the intestinal T cell differentiation.[129,198] As circulating lymphocytes may infiltrate peripheral tissues, similarly the cytokines or activated immune cells can be transported to the CNS and modulate the immune homeostasis.[199] While the BBB restricts the passage of immune cells but not cytokines, the lymphatic system is an alternative route facilitating migration of these cells and bacterial components from the periphery to the CNS.[200] The meningeal lymphatic vessels reach the CNS, exchange the cerebrospinal fluid, and drain immune cells and small compounds from the brain toward the periphery. Direct supply of microbiota-derived molecules or activated immune cells could induce a central immune response, such as the activation of microglia and T cells.[197] This in turn leads to the production of pro-inflammatory cytokines promoting neuroinflammation. Cytokines may also deteriorate BBB permeability that predisposes to increased passage of harmful compounds or metabolites from the circulation through the BBB.[200] Moreover, peripheral administration of pro-inflammatory cytokines has been shown to induce sickness behavior characterized by depressive-like behavior and reduced appetite in rodents.[199] However, the range of mechanisms describing microbially mediated crosstalk between peripheral and central immune responses are widely uncharacterized.

Microbial metabolites and the relationship between preclinical and clinical evidence

A wealth of preclinical discoveries has clarified the extensive range of pathways through which microbiota-derived metabolites could drive the communication between gut and brain as illustrated in Figure 4. The human microbiome harbors a variety of microbial species capable of producing neurotransmitters, signaling molecules, or metabolizing their precursors into distinct compounds.[145,189,201] As certain bacterium may contribute significantly to the levels of gut-derived metabolites observed in the host,[138] it is compelling to speculate how much the presence, or absence, of such bacterium could modulate the gut–brain crosstalk and contribute to overall health status. For example, abundance of secondary bile acid-producing bacteria could result into increased circulation of deoxycholic acid and other secondary bile acids compromising the BBB integrity and resulting into increased translocation of microbial metabolites into the brain.[81] Keeping in mind that the overall impact of these metabolites on health could depend on the genetic background or the presence of an illness, decreased liver or kidney function could exacerbate the accumulation of toxic metabolites like p-cresol and indoxyl sulfate that have been associated with neurodegenerative or neurodevelopmental diseases.[16,17,48-50,90]
Figure 4.

In the intersection of the gut–brain axis signaling: Selected microbiota metabolites and associated neurological functions.

In the intersection of the gut–brain axis signaling: Selected microbiota metabolites and associated neurological functions. Categorizing gut microbial metabolites based on their effect on neurological function reveals significant overlapping between metabolite classes and individual metabolites (Figure 5, Table 2). In preclinical studies, SCFAs have been implicated with all discussed neurological functions but human evidence is scarce and contradictory.[21] Similarly, derivatives of amino acid metabolism, especially tryptophan, have been implicated in all other concepts except for neuronal energy metabolism. However, clinical findings support the notion that alterations in tryptophan-metabolism might be associated with cognitive and mental status.[58,62-64,141,151,152] Although preclinical models display controversial impact of secondary bile acids, they have recently been associated with neurodegenerative diseases in humans.[76,77,81,155] 4-EPS, p-cresol sulfate and indoxyl sulfate are sulfates that show conflicting effects on neurodevelopment, -transmission, and -inflammation in vitro and in vivo but the clinical results, although associative, favor the harmful properties depicted by the preclinical data.[41,43,44,51] However, the findings are largely obtained in a pathological context, yielding a wealth of disease-associated metabolites. Whether such associations are disease-specific or the metabolites, or microbiota, could be utilized in managing brain-related disorders, requires extensive and decisive work. Besides, the associations might reflect the altered metabolism or microbiota composition due to the disease status and confounders rather than contribute to the pathogenesis per se. For example, a recent stool metagenomics study in ASD children suggested that autistic traits promote restrictive dietary preferences in turn associated with microbiome composition, rather than a direct association between the ASD and microbiome.[203]
Figure 5.

Overlapping gut microbiota associated metabolites in neurological functions.

Table 2.

Gut microbial metabolites associated neurological functions, methods of preclinical models and presence in the human brain.

MetaboliteNeurological functionPreclinical methodsMeasured from human brain[51,54,155,202]Reference
3-(3′-hydroxyphenyl)propionic acidNeuroprotectionin vitro, in vivoYes[116]
3-(3-sulfooxyphenyl)propionic acidNeurodevelopmentin vivoNo[38]
3-hydroxybenzoic acidNeuroprotectionin vitro, in vivoYes[116]
3M-4-TMABNeuronal energy metabolismin vitro, in vivoNo[109]
4-aminobenzoic acidNeurotransmissionin vitro, in vivoNo[9]
4-EPSNeurodevelopmentin vivoNo[39–41]
4-TMAPNeuronal energy metabolismin vitro, in vivoNo[109]
5-AVANeurodevelopmentin vitro, in vivoYes[42]
5-AVABNeurodevelopmentin vivo, ex vivoYes[28,131]
Acetic acidNeurodevelopmentNeurotransmissionBBB integrityNeuroinflammationNeuronal energy metabolismin vitro, in vivo, ex vivoYes[45,73,83–87,110,144,163]
Butyric acidNeurotransmissionBBB integrityNeuroinflammationNeuronal energy metabolismin vitro, in vivo, ex vivoYes[52,73,74,83–87,110–112]
Deoxycholic acidNeurotransmissionBBB integrityin vitro, in vivoYes[9,75]
Dihydrocaffeic acidNeuroinflammationin vitro, in vivoNo[88]
DopamineNeurotransmissionin vivoYes[7]
EthanolNeuronal energy metabolismin vivoYes[113]
ErgothioneineNeuroprotectionin vitro, in vivoYes[117,118]
Ferulic acidNeuroprotectionin vitro, in vivoNo[18,119,120]
GABANeurotransmissionin vitro, in vivoYes[5,14,53]
Hippuric acidNeurodevelopmentin vivo, ex vivoYes[28]
HistamineNeurotransmissionin vitro, in vivoYes[15]
Imidazole propionic acidNeurodevelopmentin vivo, ex vivoNo[28]
Indole-3-aldehydeNeurotransmissionNeuroinflammationin vivo, ex vivoNo[32,57,91]
IndoleNeurodevelopment,Neurotransmissionin vitro, in vivo, ex vivoYes[32,36,55–57,91]
Indolepropionic acidNeuroinflammationNeuronal energy metabolismNeuroprotectionin vitro, in vivo, ex vivoNo[32,110,115,121]
Indoxyl sulfateNeurodevelopmentNeuroinflammationin vitro, in vivoYes[17,32,38,51,90,91]
Isobutyric acidNeurotransmissionin vitro, ex vivoYes[52]
Isovaleric acidNeurotransmissionin vitro, ex vivoYes[52]
Kynurenic acidNeurotransmissionin vitroYes[59–61]
LactateNeurotransmissionNeuronal energy metabolismin vivoYes[20,65,114,144]
N[6]-carboxymethyllysineNeuroinflammationin vitro, in vivoYes[92–94]
NorepinephrineNeurotransmissionin vitro, in vivo, ex vivoYes[7,52]
p-CresolNeurodevelopmentNeurotransmissionin vitro, in vivoYes[16,48–51]
p-Cresol glucuronideBBB integrityin vitro, in vivoNo[72]
PhenethylamineNeurotransmissionin vivoYes[15]
PhenylsulfateNeurodevelopmentin vivoNo[38]
Pipecolic acidNeurotransmissionin vivoYes[67]
Propionic acidNeurodevelopmentNeurotransmissionBBB integrityNeuroinflammationNeuronal energy metabolismin vitro, in vivo, ex vivoYes[27,45,73,83–86,95–100,111]
Pyrocatechol sulfateNeurodevelopmentin vivoNo[38]
SerotoninNeurotransmissionin vivoYes[9,68,141]
TaurineNeurodevelopmentin vivoYes[42]
TMABBB integrityin vitroYes[27]
TMAONeurodevelopmentBBB integrityNeuroinflammationin vitro, in vivo, ex vivoYes[27,28,101,102]
TUDCANeuronal energy metabolismNeuroprotectionin vitro, in vivoYes[110,123]
TryptamineNeurotransmissionin vitro, in vivoYes[71]
TyramineNeurotransmissionin vitro, in vivoYes[9]
Urolithin ANeuroinflammationin vitro, in vivo, ex vivoNo[106–108,168]
Ursodeoxycholic acidBBB integrityin vitroYes[80]
Vitamins KNeuroprotectionin vitroYes[122]

Abbreviations: 4-EPS, 4-ethylphenylsulfate; 5-AVA(B), 5-aminovaleric acid (betaine); BBB, blood–brain barrier; GABA, γ-aminobutyric acid; 3 M-4-TMAB, 3-methyl-4-(trimethylammonio)butanoate; 4-TMAP, 4-(trimethylammonio)pentanoate; TMA(O), trimethylamine(-N-oxide); TUDCA, tauroursodeoxycholic acid

Overlapping gut microbiota associated metabolites in neurological functions. Gut microbial metabolites associated neurological functions, methods of preclinical models and presence in the human brain. Abbreviations: 4-EPS, 4-ethylphenylsulfate; 5-AVA(B), 5-aminovaleric acid (betaine); BBB, blood–brain barrier; GABA, γ-aminobutyric acid; 3 M-4-TMAB, 3-methyl-4-(trimethylammonio)butanoate; 4-TMAP, 4-(trimethylammonio)pentanoate; TMA(O), trimethylamine(-N-oxide); TUDCA, tauroursodeoxycholic acid In terms of the neurological functions, metabolites linked with BBB integrity, neuronal energy metabolism, or neuroprotection, the clinical evidence are extremely limited for evaluating their significance in humans. Given the value of these functions to brain homeostasis and the range of diet-derived metabolites identified, especially amino acid- and polyphenol-derived, future interventions focusing on these pathways and compounds are strongly advocated. To date, few studies using nutritional or gut microbiome modifying strategy have shown marked beneficial effect on neurological and psychiatric disorders. Even if some studies applying nutritional, pro- or prebiotic interventions showed interesting outcomes such as decreasing anxiety levels or improving cognition, the effects are widely variable between subjects and dependent on the type of diseases.[204-206]

Conclusion and future prospects

An array of preclinical reports show that the gut microbial metabolites regulate brain functions through peripheral and local signaling by immunological, neuronal, and endocrinological pathways. Cell and animal models provide valuable mechanistic information about the metabolites in isolation but there is limited clinical evidence to support such effects in humans. Nevertheless, it is evident that nutritional, metabolic, and disease status modulate the overall impact of metabolites on health and disease. Thus, to catch the full scope of the relationship between diet, gut microbiota, the circulating metabolome and the brain, extensive profiling of nutritional habits and clinical features are fundamental. In order to gain a comprehensive view on the microbial species involved, metabolites they produce, and metabolic effect exerted thereafter, necessitates combining metagenomic, metabolomic, and metatranscriptomic approaches in well-defined populations, healthy and disease, to uncover the intricate communication within the gut–brain axis and pave the way for personalized care involving the role of gut microbiota in the context of prevention and treatment of neurological disorders.
Some gut-derived metabolites such as trimethylamine-N-oxide (TMAO), indoles and phenylacetylglutamine have been strongly associated with pathological outcomes including cardiovascular diseases and death. Robust studies showed that even after adjusting for several confounding factors (i.e. other cardiovascular risk factors) these metabolites can predict death from cardiovascular diseases.[22–24] However, there are conflicting observations as phenylacetylglutamine has been highlighted as a biomarker of healthy aging being associated with a shift in microbiome composition toward increased uniqueness, a marker of good health in aged subjects.[25] It confirmed previous data showing elevated levels of this metabolite in centernarians.[26] Phenylacetylglutamine has also been associated with an increased α-diversity and abundance of ‘beneficial’ bacteria (Akkermansia, genus from Christensenellaceae) despite its potential detrimental effects on cardiovascular health.[24] Regarding TMAO, a recent work highlighted that trimethylamine (TMA) is detrimental for the BBB integrity while TMAO was protective and promoted cognitive performance in mice.[27] Several other preclinical studies showed that TMAO can be beneficial against atherosclerosis, nonalcoholic fatty liver disease and glucose homeostasis impairments and is required for neurodevelopment.[28–31] Indole derivatives, despite their associations with cardiovascular diseases, have been shown to exert anti-inflammatory effects on liver and to be beneficial in inflammatory bowel disease or experimental autoimmune encephalomyelitis model of multiple sclerosis.[32–35]The levels of these metabolites are influenced by several factors such as dietary intake of nutrients (e.g., choline, phenylalanine and tryptophan), gut microbiota composition and function, elimination including metabolization (e.g., in the liver) and renal excretion. Interestingly, studies found that TMAO levels are greatly influenced by the presence of a type-2 diabetes or a kidney disease and that elevation of this compound can be due to confounding factor or a reverse causation.[36] Fish consumption, recognized for its health-promoting effect, also leads to elevated levels of circulating TMAO.[37] Better understanding of the origin of metabolites and their altered levels due to dietary intake, gut microbiota production or host metabolism will help to clarify the relationship between metabolome and health on individual level. Studying the compounds’ effect, alone or in combination, at physiological dose is also important to distinguish what happens in pathological conditions (e.g., loss of renal or hepatic function) or in basal condition. Thus, future studies should gather nutritional, metabolomic, microbial and clinical data to be able to control for confounding factors.
  204 in total

Review 1.  Serotonin's Complex Role in Alcoholism: Implications for Treatment and Future Research.

Authors:  Catherine A Marcinkiewcz; Emily G Lowery-Gionta; Thomas L Kash
Journal:  Alcohol Clin Exp Res       Date:  2016-05-10       Impact factor: 3.455

2.  Expression of the short chain fatty acid receptor GPR41/FFAR3 in autonomic and somatic sensory ganglia.

Authors:  M K Nøhr; K L Egerod; S H Christiansen; A Gille; S Offermanns; T W Schwartz; M Møller
Journal:  Neuroscience       Date:  2015-01-28       Impact factor: 3.590

Review 3.  Minireview: Gut microbiota: the neglected endocrine organ.

Authors:  Gerard Clarke; Roman M Stilling; Paul J Kennedy; Catherine Stanton; John F Cryan; Timothy G Dinan
Journal:  Mol Endocrinol       Date:  2014-06-03

4.  Intracerebroventricular injection of propionic acid, an enteric metabolite implicated in autism, induces social abnormalities that do not differ between seizure-prone (FAST) and seizure-resistant (SLOW) rats.

Authors:  Sandy R Shultz; Noor A B Aziz; Li Yang; Mujun Sun; Derrick F MacFabe; Terence J O'Brien
Journal:  Behav Brain Res       Date:  2014-11-06       Impact factor: 3.332

5.  Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk.

Authors:  Xinmin S Li; Zeneng Wang; Tomas Cajka; Jennifer A Buffa; Ina Nemet; Alex G Hurd; Xiaodong Gu; Sarah M Skye; Adam B Roberts; Yuping Wu; Lin Li; Christopher J Shahen; Matthew A Wagner; Jaana A Hartiala; Robert L Kerby; Kymberleigh A Romano; Yi Han; Slayman Obeid; Thomas F Lüscher; Hooman Allayee; Federico E Rey; Joseph A DiDonato; Oliver Fiehn; W H Wilson Tang; Stanley L Hazen
Journal:  JCI Insight       Date:  2018-03-22

6.  Effect of a ketogenic meal on cognitive function in elderly adults: potential for cognitive enhancement.

Authors:  Miho Ota; Junko Matsuo; Ikki Ishida; Kotaro Hattori; Toshiya Teraishi; Hidekazu Tonouchi; Kinya Ashida; Takeshi Takahashi; Hiroshi Kunugi
Journal:  Psychopharmacology (Berl)       Date:  2016-08-27       Impact factor: 4.530

7.  Gut Microbiota-Induced Changes in β-Hydroxybutyrate Metabolism Are Linked to Altered Sociability and Depression in Alcohol Use Disorder.

Authors:  Sophie Leclercq; Tiphaine Le Roy; Sonia Furgiuele; Valentin Coste; Laure B Bindels; Quentin Leyrolle; Audrey M Neyrinck; Caroline Quoilin; Camille Amadieu; Géraldine Petit; Laurence Dricot; Vanessa Tagliatti; Patrice D Cani; Kristin Verbeke; Jean-Marie Colet; Peter Stärkel; Philippe de Timary; Nathalie M Delzenne
Journal:  Cell Rep       Date:  2020-10-13       Impact factor: 9.423

8.  Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2.

Authors:  Gwen Tolhurst; Helen Heffron; Yu Shan Lam; Helen E Parker; Abdella M Habib; Eleftheria Diakogiannaki; Jennifer Cameron; Johannes Grosse; Frank Reimann; Fiona M Gribble
Journal:  Diabetes       Date:  2011-12-21       Impact factor: 9.461

9.  Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression.

Authors:  Xinyi Wang; Guangqiang Sun; Teng Feng; Jing Zhang; Xun Huang; Tao Wang; Zuoquan Xie; Xingkun Chu; Jun Yang; Huan Wang; Shuaishuai Chang; Yanxue Gong; Lingfei Ruan; Guanqun Zhang; Siyuan Yan; Wen Lian; Chen Du; Dabing Yang; Qingli Zhang; Feifei Lin; Jia Liu; Haiyan Zhang; Changrong Ge; Shifu Xiao; Jian Ding; Meiyu Geng
Journal:  Cell Res       Date:  2019-09-06       Impact factor: 25.617

10.  Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer's Disease.

Authors:  Priyanka Baloni; Cory C Funk; Jingwen Yan; James T Yurkovich; Alexandra Kueider-Paisley; Kwangsik Nho; Almut Heinken; Wei Jia; Siamak Mahmoudiandehkordi; Gregory Louie; Andrew J Saykin; Matthias Arnold; Gabi Kastenmüller; William J Griffiths; Ines Thiele; Rima Kaddurah-Daouk; Nathan D Price
Journal:  Cell Rep Med       Date:  2020-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.